Department of Analytical Chemistry, Medical University of Gdansk, Gen. Hallera 107, 80-416, Gdansk, Poland.
Faculty of Applied Physic and Mathematics, Gdansk University of Technology, Narutowicza 11/12, 80-233, Gdansk, Poland.
AAPS PharmSciTech. 2021 Nov 19;23(1):3. doi: 10.1208/s12249-021-02143-2.
An important challenge to overcome in the solid dosage forms technology is the selection of the most biopharmaceutically efficient polymeric excipients. The excipients can be selected, among others, by compatibility studies since incompatibilities between ingredients of the drug formulations adversely affect their bioavailability, stability, efficacy, and safety. Therefore, new, fast, and reliable methods for detecting incompatibility are constantly being sought. Hence, the purpose of this work was to assess the usefulness of a heating, cooling, and reheating differential scanning calorimetry (DSC) program for detecting potential incompatibilities between atenolol, an active pharmaceutical ingredient (API), and polymeric excipients. Hot-stage microscopy (HSM), Fourier transform infrared (FTIR) spectroscopy, and powder X-ray diffraction (PXRD) were used as supporting techniques. Additionally, principal component analysis (PCA) and hierarchical cluster analysis (HCA) served as tools to support the interpretation of the data acquired from the DSC curves and FTIR spectra. As the alterations in the shape of the DSC peak of atenolol which are indicative of incompatibility are visible only on the cooling and reheating curves of the mixtures, the DSC heating-cooling-reheating program was found to be very useful for identifying potential incompatibilities in the binary mixtures of atenolol and polymeric excipients. The melting and recrystallization of atenolol alone and in its mixtures were also confirmed by HSM, while FTIR displayed changes in the spectra of mixtures due to incompatibility. These studies revealed that atenolol is incompatible with hydroxyethylcellulose, hypromellose, and methylcellulose. PXRD measurements at room temperature revealed that the crystallinity of atenolol did not change in these mixtures. However, its crystallinity was reduced in the mixtures previously heated up to 155 °C and then cooled to 25 °C.
在固体制剂技术中,克服的一个重要挑战是选择最具生物药剂学效率的聚合物赋形剂。赋形剂可以通过相容性研究来选择,因为药物配方成分之间的不相容性会对其生物利用度、稳定性、功效和安全性产生不利影响。因此,人们一直在不断寻求新的、快速和可靠的方法来检测不相容性。因此,本工作的目的是评估加热-冷却-再加热差示扫描量热法(DSC)程序用于检测阿替洛尔(一种活性药物成分(API))与聚合物赋形剂之间潜在不相容性的有用性。热台显微镜(HSM)、傅里叶变换红外(FTIR)光谱和粉末 X 射线衍射(PXRD)被用作支持技术。此外,主成分分析(PCA)和层次聚类分析(HCA)用作支持从 DSC 曲线和 FTIR 光谱中获取的数据解释的工具。由于阿替洛尔的 DSC 峰形状的改变表明不相容性仅在混合物的冷却和再加热曲线上可见,因此发现 DSC 加热-冷却-再加热程序非常有助于识别阿替洛尔与聚合物赋形剂的二元混合物中的潜在不相容性。单独的阿替洛尔及其混合物的熔融和重结晶也通过 HSM 得到证实,而 FTIR 显示了由于不相容性导致混合物的光谱发生变化。这些研究表明,阿替洛尔与羟乙基纤维素、羟丙甲纤维素和甲基纤维素不相容。室温下的 PXRD 测量表明,在这些混合物中,阿替洛尔的结晶度没有变化。然而,在先前加热至 155°C 然后冷却至 25°C 的混合物中,其结晶度降低。